Anti-MIC antibodies and methods of use

Patent metadata

Field	Value
Publication number	US-11555076-B2
Application number	US-201716345619-A
Country	US
Kind code	B2
Filing date	Oct 27, 2017
Priority date	Oct 29, 2016
Publication date	Jan 17, 2023
Grant date	Jan 17, 2023

Abstract

The invention provides anti-MIC antibodies and methods of using the same.

First claim

What is claimed is:

1. An antibody that specifically binds to human MICA*008, wherein the antibody comprises the following six hypervariable regions (HVRs):
a HVR-H1 comprising the amino acid sequence of SEQ ID NO: 209;
a HVR-H2 comprising the amino acid sequence of SEQ ID NO: 210;
a HVR-H3 comprising the amino acid sequence of SEQ ID NO: 211;
a HVR-L1 comprising the amino acid sequence of SEQ ID NO: 212;
a HVR-L2 comprising the amino acid sequence of SEQ ID NO: 213; and
a HVR-L3 comprising the amino acid sequence of SEQ ID NO: 214.

2. The antibody of claim 1 , wherein the antibody comprises a VH sequence of SEQ ID NO: 369 and a VL sequence of SEQ ID NO: 370.

3. The antibody of claim 1 , wherein the antibody is monoclonal.

4. The antibody of claim 1 , wherein the antibody is humanized or chimeric.

5. The antibody of claim 1 , wherein at least a portion of the framework sequence is a human consensus framework sequence.

6. The antibody of claim 1 , wherein the antibody is a full-length antibody.

7. The antibody of claim 1 , wherein the antibody is a fragment is selected from the group consisting of Fab, Fab′, Fab′-SH, Fv, single chain variable fragment (scFv), and (Fab′) 2 fragments.

8. The antibody of claim 1 , wherein the antibody is an IgG class antibody.

9. The antibody of claim 8 , wherein the IgG class antibody is an IgG1 subclass antibody.

10. An isolated nucleic acid encoding the antibody of claim 1 .

11. A vector comprising the nucleic acid of claim 10 .

12. A host cell comprising the vector of claim 11 .

13. A method of producing an antibody, the method comprising culturing the host cell of claim 12 in a culture medium.

14. An immunoconjugate comprising the antibody of claim 1 and a cytotoxic agent.

15. A composition comprising the antibody of claim 1 .

16. The composition of claim 15 , wherein the composition further comprises a PD-1 axis binding antagonist or an additional therapeutic agent.

17. A kit comprising the antibody of claim 1 and a package insert comprising instructions for using the antibody for treating or delaying progression of a cancer in a subject.

18. A kit comprising the antibody of claim 1 and a package insert comprising instructions for using the antibody for treating or delaying progression of an immune related disease in a subject.

19. A kit comprising the antibody of claim 1 and a package insert comprising instructions for increasing, enhancing, or stimulating an immune response or function in a subject.

20. The antibody of claim 1 , wherein the antibody is a bispecific antibody.

21. The antibody of claim 8 , wherein the IgG class antibody is an IgG2 subclass antibody.

22. The antibody of claim 8 , wherein the IgG class antibody is an IgG4 subclass antibody.

23. The antibody of claim 2 , wherein the antibody is monoclonal.

24. The antibody of claim 2 , wherein the antibody is humanized or chimeric.

25. The antibody of claim 2 , wherein the antibody is a bispecific antibody.

26. The antibody of claim 2 , wherein at least a portion of the framework sequence is a human consensus framework sequence.

27. The antibody of claim 2 , wherein the antibody is a full-length antibody.

28. The antibody of claim 2 , wherein the antibody is a fragment is selected from the group consisting of Fab, Fab′, Fab′-SH, Fv, single chain variable fragment (scFv), and (Fab′) 2 fragments.

29. The antibody of claim 2 , wherein the antibody is an IgG class antibody.

30. The antibody of claim 29 , wherein the IgG class antibody is an IgG 1 subclass antibody.

31. The antibody of claim 29 , wherein the IgG class antibody is an IgG 2 subclass antibody.

32. The antibody of claim 29 , wherein the IgG class antibody is an IgG 4 subclass antibody.

Assignees

• Genentech Inc

Inventors

• Lombana Twyla Noelle
• Spiess Christoph
• Kim Jeong
• Toy Evangeline
• Schartner Jill
• Ye Zhengmao
• Bevers Iii Jack
• Cook Ryan
• Matsumoto Marissa
• Berkley Amy

Classifications

• C07K2317/55

  Fab or Fab' · CPC title

• C07K2317/76

  Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title

• C07K2317/24

  containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61K47/6849

  the antibody targeting a receptor, a cell surface antigen or a cell surface determinant · CPC title